Cargando…

Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D

Detalles Bibliográficos
Autores principales:	Tseng, Chien-Wen, Masuda, Camlyn, Chen, Randi, Hartung, Daniel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	e-Letters: Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646207/ https://www.ncbi.nlm.nih.gov/pubmed/32041898 http://dx.doi.org/10.2337/dc19-1294

Ejemplares similares

Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D
por: Trish, Erin, et al.
Publicado: (2021)

Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
por: Shao, Hui, et al.
Publicado: (2022)

Out of Pocket Diabetes-Related Medical Expenses for Adolescents and Young Adults With Type 1 Diabetes: The SEARCH for Diabetes in Youth Study
por: Merjaneh, Lina, et al.
Publicado: (2019)

Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products
por: Gupta, Arjun, et al.
Publicado: (2022)

Estimates of Insulin Out-of-Pocket Cap–Associated Prescription Satisfaction, Adherence, and Affordability Among Medicare Beneficiaries
por: Li, Minghui, et al.
Publicado: (2023)

Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis
por: Tseng, Chien-Wen, et al.
Publicado: (2020)

Progressivity of out-of-pocket costs for Medicare-subsidised services and medicines in Australia.
por: Di Law, Hsei, et al.
Publicado: (2022)

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program
por: Luo, Jing, et al.
Publicado: (2020)

Out-of-Pocket Costs for Colonoscopy After Noninvasive Colorectal Cancer Screening Among US Adults With Commercial and Medicare Insurance
por: Fendrick, A. Mark, et al.
Publicado: (2021)

Colorectal cancer screening use among insured adults: Is out-of-pocket cost a barrier to routine screening?
por: Perisetti, Abhilash, et al.
Publicado: (2018)

Management of Diabetic Ketoacidosis in Severe Insulin Resistance
por: Robinson, Cemre, et al.
Publicado: (2016)

Changes in Out-of-Pocket Spending and Catastrophic Health Care Expenditures Associated With Medicare Eligibility
por: Scott, John W., et al.
Publicado: (2021)

Feasibility of Outpatient 24-Hour Closed-Loop Insulin Delivery
por: de Bock, Martin I., et al.
Publicado: (2015)

Swimming With the Omnipod 5 Automated Insulin Delivery System: Connectivity in the Water
por: Hughes, Michael S., et al.
Publicado: (2023)

Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
por: Lakdawalla, Darius, et al.
Publicado: (2021)

Trends in Insulin Use and Diabetes Control in the U.S.: 1988–1994 and 1999–2012
por: Selvin, Elizabeth, et al.
Publicado: (2016)

Food Order Has a Significant Impact on Postprandial Glucose and Insulin Levels
por: Shukla, Alpana P., et al.
Publicado: (2015)

Continuous Glucose Monitoring in Patients With Type 1 Diabetes Using Insulin Injections
por: Foster, Nicole C., et al.
Publicado: (2016)

Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage
por: Chua, Kao-Ping, et al.
Publicado: (2021)

Virtual Look AHEAD Program: Initial Support for a Partly Virtualized Intensive Lifestyle Intervention in Type 2 Diabetes
por: Williams, Geoffrey C., et al.
Publicado: (2014)

Effect of Cost and Formulation on Persistence and Adherence to Initial Metformin Therapy for Type 2 Diabetes
por: Flory, James H., et al.
Publicado: (2020)

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
por: Rome, Benjamin N., et al.
Publicado: (2021)

What Is the Price of Science?
por: Alwine, James C., et al.
Publicado: (2021)

Trends in Out-of-Pocket Cost of Glucagon, 2010-2020
por: Zupa, Margaret, et al.
Publicado: (2022)

Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023)

Out-of-pocket health spending among Medicare beneficiaries: Which chronic diseases are most costly?
por: Fong, Joelle H.
Publicado: (2019)

Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
por: Alpern, Jonathan D., et al.
Publicado: (2022)

An Insulin Resistance Score Improved Diabetes Risk Assessment in the Malmö Prevention Project—A Longitudinal Population-Based Study of Older Europeans
por: Shiffman, Dov, et al.
Publicado: (2021)

Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study
por: Garofolo, Monia, et al.
Publicado: (2020)

HbA(1c), Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy
por: Janssen, Jolien, et al.
Publicado: (2019)

Predictive Value of Admission Hemoglobin A(1c) on Inpatient Glycemic Control and Response to Insulin Therapy in Medicine and Surgery Patients With Type 2 Diabetes
por: Pasquel, Francisco J., et al.
Publicado: (2015)

Simultaneous Consideration of HbA(1c) and Insulin Resistance Improves Risk Assessment in White Individuals at Increased Risk for Future Type 2 Diabetes
por: Meigs, James B., et al.
Publicado: (2020)

Role of Noninsulin Therapies Alone or in Combination in Chromosome 6q24-Related Transient Neonatal Diabetes: Sulfonylurea Improves but Does Not Always Normalize Insulin Secretion
por: Carmody, David, et al.
Publicado: (2015)

Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting
por: Castellanos, Luz E., et al.
Publicado: (2021)

Fasting Status of Patients Undergoing Ambulatory Laboratory Testing
por: Tseng, Eva, et al.
Publicado: (2019)

Real price of health-experiences of out-of-pocket costs in Australia: protocol for a systematic review
por: Wang, Shelley Ting-Li, et al.
Publicado: (2022)

Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
por: Salam, Tabassum, et al.
Publicado: (2023)

16. Attributable Mortality, Healthcare Costs and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2021)

The influence of Medicare Part D on the list pricing of brand drugs
por: Ippolito, Benedic N., et al.
Publicado: (2023)

Spending and Out-of-Pocket Prices for Brand-Name Drugs Among Commercially Insured Individuals in Massachusetts, 2015-2017
por: Aaron, Micah B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ej7o5nq7dcre1luvg1u6a61jak